Expanding the limits of cancer therapies


Hemerion develops novel cancer therapies that blend photonics, medecine and biotechnology. Its first breakthrough technology addresses glioblastoma as a complement to neurosurgery. Its efficacy is currently being evaluated in clinical trials.

Nature Journal

Nature highlights the first clinical trials of Hemerion's technologies

Read more

Dr Maximilien Vermandel, Hemerion's founder, presents the news perspectives opened up by Hemerion to treat glioblastomas."